Clinical trials: sponsored by Ionis Pharmaceuticals, Inc.
Hypertriglyceridemia
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
The purpose of this study is to evaluate the dose/response pharmacodynamic effects of ISIS ApoC-III Rx vs. Placebo on fasting total apoC-III levels.
- Trial name
- NCT01529424
- Testing
- ISIS apoC-III Rx
- Where
- 7 sites in United States, Canada
- Volunteers
- 89 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Type 2 Diabetes
Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes
The purpose of this study is to evaluate the effects of ISIS ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects with Type 2 Diabetes on stable treatment with metformin.
- Trial name
- NCT01647308
- Testing
- ISIS-APOCIIIRX
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers
To evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics, including Factor XI activity and antigen levels, activated partial thromboplastin time, prothrombin time and international normalized ratio of…
- Trial name
- NCT03582462
- Testing
- IONIS FXI-LRx
- Where
- Canada
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Healthy Subjects, Cystic Fibrosis
A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis
This Phase 1/2a study is a double-blinded (subject and Investigator), randomized, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple…
- Trial name
- NCT03647228
- Testing
- IONIS-ENaCRx
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypertriglyceridemia, Familial Hypercholesterolemia
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS ANGPTL3-LRx (ISIS 703802) given to healthy volunteer subjects with elevated triglycerides and subjects with familial…
- Trial name
- NCT02709850
- Testing
- IONIS ANGPTL3-LRx
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hepatic Steatosis
Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes
The purpose is to assess the Safety, Tolerability, and Pharmacodynamics effect of IONIS DGAT2Rx in up to 45 Adult Patients with Type 2 Diabetes.
- Trial name
- NCT03334214
- Testing
- IONIS DGAT2Rx
- Where
- 22 sites in Canada, Hungary and 2 more
- Volunteers
- 44 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Elevated Lipoprotein(a)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-APO(a)Rx given to participants with high lipoprotein(a) for 12 weeks.
- Trial name
- NCT02160899
- Testing
- ISIS-APO(a)Rx
- Where
- 13 sites in Canada, Denmark and 3 more
- Volunteers
- 64 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Geographic Atrophy, Age Related Macular Degeneration
Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
The purpose of this study is to assess the Safety and Efficacy of IONIS-FB-Lrx for up to 120 patients with Geographic Atrophy secondary to Age Related Macular Degeneration
- Trial name
- NCT03446144
- Testing
- IONIS-FB-Lrx
- Where
- 37 sites in United States, Australia and 1 more
- Sponsor
- Ionis Pharmaceuticals, Inc.
Amyloidosis, Hereditary
ATTR Expanded Access Program (EAP) by Ionis
The purpose of this program is to provide expanded access to Inotersen for up to 100 Patients with Hereditary Transthyretin Amyloidosis (hTTR).
- Trial name
- NCT03400098
- Testing
- Inotersen
- Sponsor
- Ionis Pharmaceuticals, Inc.
FAP, Familial Amyloid Polyneuropathy
Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
The purpose of this study is to evaluate the efficacy and safety of inotersen given for 65 weeks in participants with Familial Amyloid Polyneuropathy (FAP).
- Conditions
- FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin
- Trial name
- NCT01737398
- Testing
- Inotersen
- Where
- 24 sites in United States, Argentina and 8 more
- Volunteers
- 173 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Huntington's Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease
This study tested the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ISIS 443139 administered intrathecally to adult participants with early manifest Huntington's Disease.
- Trial name
- NCT02519036
- Testing
- ISIS 443139 10 mg, ISIS 443139 30 mg, ISIS 443139 60 mg
- Where
- 9 sites in Canada, Germany and 1 more
- Volunteers
- 46 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Thalassemia
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers
The purpose is to assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS TMPRSS6-Lrx Administered Subcutaneously for up to 44 Healthy Volunteers
- Trial name
- NCT03165864
- Testing
- IONIS TMPRSS6-Lrx
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Elevated Lipoprotein(a)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS APO(a)-LRx (ISIS 681257) given to healthy volunteer subjects.
- Trial name
- NCT02414594
- Testing
- IONIS-APO(a)-LRx, Sterile Normal Saline (0.9% NaCl)
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Healthy Volunteers
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers
The purpose is to assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS AGT-LRx in up to 82 Healthy Volunteers
- Trial name
- NCT03101878
- Testing
- Ionis AGT-LRx
- Where
- Canada
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Non-small Cell Lung Cancer
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel
The purpose of this study is to examine the overall survival of patients with Stage IV non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin and paclitaxel.
- Trial name
- NSCLC (NCT01234038)
- Testing
- ISIS EIF4E Rx, Paclitaxel, Carboplatin
- Where
- 29 sites in United States, Hungary and 2 more
- Volunteers
- 116 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Obesity
A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients
The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-FGFR4RX.
- Trial name
- FGFR4-CS2 (NCT02476019)
- Testing
- ISIS-FGFR4RX
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Type 2 Diabetes
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy, safety, and tolerability of ISIS-GCGRRx in combination with metformin versus placebo
- Trial name
- NCT02583919
- Testing
- ISIS-GCGRRx- Dose Level 1, ISIS-GCGRRx- Dose Level 2
- Where
- 19 sites in United States
- Volunteers
- 79 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Advanced Cancers, DLBCL
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
This is a Phase 1/2, open-label, dose-escalation, dose-expansion study for the treatment of patients with advanced cancers. Eligible patients with DLBCL or other advanced lymphomas will be enrolled into the dose-expansion cohort.
- Conditions
- Advanced Cancers, DLBCL, Lymphoma
- Trial name
- NCT01563302
- Testing
- IONIS-STAT3Rx
- Where
- 9 sites in United States
- Volunteers
- 64 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Elevated Triglycerides (TG)
Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS APOC-III-LRx given to healthy volunteer subjects.
- Trial name
- NCT02900027
- Testing
- APOC-III-L-Rx
- Where
- Canada
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Type 2 Diabetes
Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes
The purpose of this study is to evaluate the effect of ISIS 449884 (ISIS-GCGRRX) on Hepatic Lipid and Glycogen Content in patients with Type 2 Diabetes being treated with Metformin.
- Trial name
- NCT02824003
- Testing
- ISIS-GCGRRx
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Ionis Pharmaceuticals, Inc.